



Neslihan Başçıl Tütüncü

Adress: Başkent University Faculty of Medicine

Department of Endocrinology and Metabolism; 5. Sokak 1. Kat 06490
Bahçelievler ANKARA TURKEY

Birth Date: 05. 10. 1967

Language: English

High School:

1978-1985 İzmir American Collage of Institute

Education at University/Medical School level:

1985-1991 Hacettepe University Faculty of Medicine (English)

Details of Medical license:

1992-1996 Hacettepe University Faculty of Medicine Department of Internal Medicine ;

1997-1999 Hacettepe University Faculty of Medicine Department of Endocrinology and
Metabolism

Examinations for specialities:

Speciality Exam in the Field of Medicine 1992 (Hacettepe University Faculty of Medicine
Department of Internal Medicine)

Examination for Associate professor attendance: 2002

Position: Medical Doctor, Professor and Doctorate student in the field of Molecular Biology

PUBLICATIONS:

1. **Başçıl Tütüncü N.**, Bayraktar M., Varlı K. Reversal of defective nerve conduction with vitamin E supplementation in Type 2 diabetes. *Diabetes Care*, 21, 1915-1918 (1998).
2. **Başçıl Tütüncü N.**, Bayraktar M., Pehlivanoglu B. The effect of vitamin E supplementation on erythrocyte osmotic fragility in diabetic patients. *Clinical Hemorrhology and Microcirculation*, 20, 201-207 (1999).
3. **Başçıl Tütüncü N.**, Gedik O. Adrenal incidentaloma: Report of 33 cases. *Journal of Surgical Oncology*, 70: (4), 247-250 (1999).
4. Özgen, A., Alp M.N., Arıyürek M., **Başçıl Tütüncü N.**, Can I., Günalp I. Quantitative CT of the orbit in Grave's disease. *British Journal of Radiology*, 72: (860) 757-762 (1999).
5. Güvener N., **Başçıl Tütüncü N.**, Oto A., Erbaş T. Major determinants of the carotid intima-media thickness in Type 2 diabetic patients: Age and body mass index. *Endocrine Journal*, 47 (5), 525-533 (2000).
6. **Başçıl Tütüncü N.**, Güvener N., Tütüncü T., Yılmaz M., Güvener M., Böke E., Paşaoğlu İ., Erbaş T. Chlamydia Pneumonia seropositivity correlates with serum fibrinogen and lipoprotein a levels: Any role in atherosclerosis? *Endocrine Journal*, 48: (2), 269-274 (2001).
7. **Başçıl Tütüncü N.**, Gurlek O.A., Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: A prospective study. *Acta Diabetologica*, 38, 157-161, (2001).
8. Gökcel A., Karaköse H., Ertörer E.M., Tanacı N., **Başçıl Tütüncü N.**, Güvener N. Effects of sibutramine on poorly controlled obese type 2 diabetic women. *Diabetes Care*, 24 (11), 1957-1960 (2001).
9. Gökcel A., Gümürdülü Y., Karaköse H., Ertörer E.M., Tanacı N., **Başçıl Tütüncü N.**, Güvener N. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin on the treatment of obesity. *Diabetes, Obesity and Metabolism*, 2002;4 (1), 49-55.
10. Guvener N, **Tutuncu NB**, Akcay S, Eyuboglu F, Gokcel A. Alveolar Gas Exchange in Patients with Type 2 Diabetes Mellitus. *Endocr J.* 2003 Dec;50(6):663-667.
11. Tanacı N, Karaköse H, Guvener N, **Tutuncu NB**, Çolak T, Haberal M .Influence of 1,25-dihydroxyvitamin D3 as an immunomodulator in renal transplant recipients: a retrospective cohort study. *Transplant Proc.* 2003 Dec;35(8):2885-2887.
12. **Tutuncu NB**, Erbaş T. Factors associated with bone metabolism in acromegalic

- patients. Hypogonadism and female gender. *Exp and Clin Endocrinol* 2004 Jun;112(6):328-332
13. **Tutuncu NB**, Karataş M, Sözyay S. Prolonged P300 latency in mild thyroid failure:A paradox: P300 latency recovers later in mild hypothyroidism than in severe hypothyroidism. *Thyroid* 2004 August; 14(8):580-585
 14. Sahin M, **Tutuncu NB**, Demirağ NG. Autoimmune hypoglycemia in a type 2 diabetic patient with anti-insulin and insulin receptor antibodies. *Diabetes Care*. 2004 May;27(5):1246-1247
 15. **Neslihan Başçıl Tütüncü**, Mustafa Kemal Batur, Aylin Yıldırım, Tanju Tütüncü, Ahmet Değer , Zehra Koray , Belkis Erbaş, Giray Kabakci, Serdar Aksoyek, and Tomris Erbaş. Melatonin Levels Decrease in Type 2 Diabetic Patients with Cardiac Autonomic Neuropathy. *J Pineal Research* 2005; 39(1):43-49.
 16. **Neslihan Başçıl Tütüncü**, Tomris Erbaş, Mehmet Alikasifoğlu, Ergun Tunçbilek. Thermolabile methylenetetrahydrofolate reductase enzyme genotype frequent in type 2 diabetic patients with normal fasting homocysteine levels. *J Intern Med* 2005; 257(5):446-453.
 17. Sahin M, Guvener ND, Ozer F, Sengul A, Ertugrul D, **Tutuncu NB**. Thyroid cancer in hyperthyroidism: Incidence rates and value of ultrasound-guided fine-needle aspiration biopsy in this patient group. *J Endocrinol Invest*. 2005 Oct;28 (9):815-818
 18. Sahin M, Sengül A, Berki Z, **Tütüncü NB**, Guvener ND. Ultrasound-guided fine-needle aspiration biopsy and ultrasonographic features of infracentimetric nodules in patients with nodular goiter: correlation with pathologic findings. *Endocr Pathol*. 2006 Spring; 17(1):67-74.
 19. Sahin M, Gursoy A, **Tutuncu NB**, Guvener DN. Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules. *Clin Endocrinol (Oxf)*. 2006 Oct;65(4):514-8.
 20. Gursoy A, Kulaksızoglu M, Sahin M, Ertugrul DT, Ozer F, **Tutuncu NB**, Demirağ NG. Severe hypertriglyceridemia-induced pancreatitis during pregnancy. *J Natl Med Assoc*. 2006 Apr; 98(4):655-657.
 21. Gursoy A, Sahin M, Ertugrul DT, Berberoglu Z, Sezgin A, **Tutuncu NB**, Demirağ NG. Familial dilated cardiomyopathy hypergonadotrophic hypogonadism associated with thyroid hemiagenesis. *Am J Med Genet A*. 2006 Apr 15;140(8):895-896.
 22. **Tutuncu NB**, Tutuncu T, Ozgen A, Erbas T. Treatment options in Graves' Disease in a region with iodine deficiency. *J Natl Med Assoc*. 2006 June; 98(6):926-930

23. Gursoy A, Unal AD, Ayturk S, Karakus S, İzol AT, **Tutuncu NB**, Guvener ND. Polycytemia as the first manifestation of Cushing's disease. *J Endocrinol Invest* 2006 Sep;29(8):742-744.
24. Ayturk S, Gursoy A, **Tutuncu NB**, Ertugrul D, Demirağ NB. Changes in Insulin Sensitivity and Glucose and Bone Metabolism over Time in Patients with Asymptomatic Primary Hyperparathyroidism. *J Clin Endocrinol Metab.* 2006 Nov; 91 (11),4260-4263.
25. Ertugrul DT, Gursoy A, Yucel M, Sahin M, Unal AD, Pamuk B, Berberoglu Z, Ayturk S, **Tutuncu NB**, Demirag NG. Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis. *Platelets.* 2006 Sep;17(6):351-3.
26. Gursoy A, Ertugrul DT, Pamuk B, Sahin M, Asik M, Yilmaz H, Haydardedeoglu F, **Tutuncu NB**, Demirag NG. Mean platelet volume in patients with polycystic ovary disease. *Platelets.* 2006 Nov;17(7):505-6.
27. Sahin M, **Tutuncu NB**, Kanbay M, Guvener ND. Surgery for hyperthyroidism in Down syndrome: case report. *Mt Sinai J Med.* 2006 Sep;73(5):784-6.
28. Bozkirli E, Ertorer ME, Bakiner O, **Tutuncu NB**, Demirag NG. The validity of the World Health Organisation's obesity body mass index criteria in a Turkish population: a hospital-based study. *Asia Pac J Clin Nutr.* 2007;16(3):443-7.
29. Sahin M, Tanaci N, Yucel M, **Tutuncu NB**, Guvener N. The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients. *Clin Endocrinol (Oxf).* 2007 Sep;67(3):346-50.
30. Sahin M, Yilmaz H, Gursoy A, Demirel AN, **Tutuncu NB**, Guvener ND. Gynaecomastia in a man and hyperoestrogenism in a woman due to ingestion of nettle (*Urtica dioica*). *N Z Med J.* 2007 Nov 9;120(1265):U2803.
31. Gursoy A, Ertugrul DT, Sahin M, **Tutuncu NB**, Demirer AN, Demirag NG. The analgesic efficacy of lidocaine/prilocaine (EMLA) cream during fine-needle aspiration biopsy of thyroid nodules. *Clin Endocrinol (Oxf).* 2007 May; 66(5):691-4. Epub 2007 Mar 23.
32. Gursoy A, Ertugrul DT, Sahin M, **Tutuncu NB**, Demirer AN, Demirag NG. Needle-free delivery of lidocaine for reducing the pain associated with the fine-needle aspiration biopsy of thyroid nodules: time-saving and efficacious procedure. *Thyroid.* 2007 Apr;17(4):317-21.

33. Ertorer ME, Anaforoglu I, Bozkirli E, Bakiner O, **Tutuncu NB**, Demirag NG. A new perspective in diagnosing polycystic ovary syndrome. J Natl Med Assoc. 2007 Feb;99(2):149-52.
34. Sahin M, **Tutuncu NB**, Ertugrul D, Tanaci N, Guvener ND. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications. 2007 Mar-Apr;21(2):118-23.
35. Berberoğlu Z., Gursoy A, Bayraktar N, Yazici AC, **Başçıl Tütüncü N**, Guvener Demirağ N. Rosiglitazone decreases serum bone specific alkaline phosphatase activity in postmenopausal women. J Clin Endocrinol Metab. 2007 Sep; 92(9):3523-3530.
36. Ertörer ME, **Tütüncü NB**, Özyılkan Ö. Incidental papillary microcarcinoma of the thyroid. Asian Pac J Cancer Prev 2007;8(4):631-4.
37. Ertorer ME, Bakiner O, Anaforoglu I, Bozkirli E, **Tutuncu NB**, Demirag NG. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. Neuro Endocrinol Lett. 2007 Dec;28(6):727-33. Review.
38. Ertorer ME, Bakiner O, Anaforoglu I, Sezgin N, Demirag NG, **Tutuncu NB**. Serum osteoprotegerin concentration with strontium ranelate treatment for postmenopausal osteoporosis: an open, prospective study. Curr Ther Res Clin Exp. 2007 Jul;68(4):217-25.
39. Anaforoğlu I, Nar Demirer A, **Başçıl Tütüncü N**, Ertörer ME. Prevalence of osteoporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes. J Diabetes Complications 2008; Apr 15.
40. Bakiner O, Ertörer ME, Haydardedeoğlu FE, Bozkırlı E, **Tutuncu NB**, Demirağ NG. Subclinical hypothyroidism is characterized by increased QT interval dispersion among women. Med Princ Pract 2008; 17(5): 390-4.
41. Bakiner O, Ertörer ME, Bozkırlı E, **Tütüncü NB**, Demirağ NG. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetol 2008; Sep 30.
42. Gürsoy A, **Tütüncü NB**, Gençoğlu A, Anıl C, Nar A, Demirağ NG. Radioactive iodine in the treatment of type-2 amiodorone induced thyrotoxicosis. J Natl Med Assoc 2008 Jun; 100(6):716-719.

43. Gürsoy A, Anıl C, Ünal AD, **Tütüncü NB**, Erdoğan MF. Clinical and Epidemiological Characteristics of Thyroid hemigenesis:ultrasound screening in patients with thyroid disease and normal population. *Endocrine* 2008; Nov 18.
44. Nar A, Kemal Y, Gursoy A, Sahin M, **Tutuncu NB**. Clinicopathological characteristics of thyroid cancer in patients on dialysis for end-stage renal disease. *Thyroid* 2008; 18:45-50.
45. Sahin M, Karataş M, Ertugrul D, Kulaksızoğlu M, Doğruk A, Gokcel A, **Tutuncu NB**, Guvener ND, Kutlu M. High prevalence of neuropathy in patients with impaired 60-minute oral glucose tolerance test but normal fasting and 120-minute glucose levels. *Minerva Endocrinol* 2008 Dec;33(4):289-296.
46. Sahin M, Tanacı N, Yücel M, Kutlu M, **Tutuncu NB**, Pamuk B, Guvener ND. Acute effects of orlistat on postprandial serum leptin levels in nondiabetic obese patients. *Minerva Endocrinol* 2008 Sep;33(3):169-173.
47. Aktaş A, Kavak K, Kocabaş B, Aras M, **Tütüncü NB**, Gençoğlu A. The biodistribution of radioiodine on posttherapy iodine –131 scans in thyroid cancer patients with chronic renal failure. *Nucl Med Commun.* 2008 Nov; 29(11):943-948.
48. Torun AN, Kulaksızoğlu S, Kulaksızoğlu M, Pamuk BO, İsbilen E, **Tütüncü NB**. Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. *Clin Endocrinol (Oxf)*. 2008 Aug.
49. Davies M, Lavallo Gonzalez F, Storms F, Gomis R; **AT.LANTUS Study Group**. Initiation of insulin glargin therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. *Diabetes Obes Metab* 2008 May; 10(5): 387-399.
50. Ertuğrul DT, Gursoy A, Sahin M, Unal AD, Pamuk B, Berberoğlu Z, Ayturk S, **Tutuncu NB**, Demirağ NG. Evaluation of brain natriuretic peptide levels in hyperthyroidism and hypothyroidism. *J Natl Med Assoc.* 2008 Apr;100(4):401-405.
51. Nar Demirel A, Ayturk S, **Tutuncu NB**, Gursoy A, Pak Y, Demirağ NG. Unresectable huge sternal and mediastinal metastasis of follicular thyroid carcinoma: radiotherapy as first-line and palliative therapy. *Exp Clin Endocrinol Diabetes.* 2009 Apr;117(4):155-8.
52. Pamuk BO, Torun AN, Kulaksizoglu M, Algan C, Ertugrul DT, Yilmaz Z, **Tutuncu NB**, Demirağ NG. 49,XXXXY syndrome with autoimmune diabetes and ocular manifestations. *Med Princ Pract.* 2009;18(6):482-5.

53. Ayturk S, Gursoy A, Kut A, Anil C, Nar A, **Tutuncu NB**. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. Eur J Endocrinol. 2009 Oct;161(4):599-605.
54. Yılmaz H, **Tütüncü NB**, Sahin M. Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J Endocrinol Invest. 2009 Dec;32(11):913-6.
55. Sahin M, Sade LE, **Tutuncu NB**, Gursoy A, Kebapcilar L, Muderrisoglu H, Guvener ND. Systolic pulmonary artery pressure and echocardiographic measurements in patients with euthyroid Hashimoto's thyroiditis. J Endocrinol Invest. 2009 Jun;32(6):530-2. DOI:10.3275/6134;
56. Bakiner O, Ertorer ME, Bozkirli E, **Tutuncu NB**, Demirag NG. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetol. 2009 Mar;46(1):63-5.
57. Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E, **Tutuncu NB**. Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol (Oxf). 2009 Mar;70(3):469-74.
58. Anaforoglu I, Ertorer ME, Kozanoglu I, Unal B, Haydardedeoglu FE, Bakiner O, Bozkirli E, **Tutuncu NB**, Demirag NG. Macroprolactinemia, like hyperprolactinemia, may promote platelet activation. Endocrine. 2010 Apr;37(2):294-300.
59. Erdogan A, Kose F, Akkaya H, **Bascil Tutuncu N**, Ozyilkan O.J. Rapidly progressing malignant insulinoma presented with multiple liver metastases: a case report. Gastrointest Cancer. 2010 Dec;41(4):272-4.
60. Ertorer ME, Haydardedeoglu FE, Erol T, Anaforoglu I, Binici S, **Tutuncu NB**, Sezgin A, Demirag NG. Newly diagnosed hyperglycemia and stress hyperglycemia in a coronary intensive care unit.. Diabetes Res Clin Pract. 2010 Oct; 90(1):8-14.
61. Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Topol EJ, Bousser MG, Fox KA, Lancet. 2010 Aug 14;376(9740):517-23.
62. Maral I, **Tütüncü NB**, Bakar C, Durukan E, Budakoğlu II, Ozkan S, Aycan S, Aygün R, Bumin MA. The 5-year incidence of type 2 diabetes mellitus in women older than

15 years in Ankara, Turkey: a population-based study. J Investig Med. 2010 Aug;58(6):796-800.

63. Nar A, Ozen O, **Tutuncu NB**, Demirhan B. Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma. Med Oncol. 2012 Mar;29(1):294-300.
64. **ORIGIN Trial** Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28.
65. **ORIGIN Trial** Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggioni AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012 Jul 26;367(4):309-18.
66. [Isildak, SM](#) , [Ayturk, S](#), [Bascil, S](#) , **Tutuncu, NB**. Insülin Glargine in gastrostomy feeding. Acta Endocrinologica –Bucharest. 2012;8(2):257-263
67. Mousa, U, Kut, A ; Bozkus, Y ; Demir, CC ; Anil, C, **Tutuncu, NB**. Performance of Abdominal Bioelectrical Impedance Analysis and Comparison with Other Known Parameters in Predicting the Metabolic Syndrome, Experimental and Clinical Endocrinology, 2013;121(7):391-396. DOI: 10.1055/s-0033-1341473
68. Duran AO, Anil C, Gursoy A, Nar A, Altundag O, **Tutuncu NB**. The relationship between glucose metabolism disorders and malignant thyroid disease. Int J Clin Oncol. 2013 Aug;18(4):585-9.
69. Thyroid volume in patients with glucose metabolism disorders. Duran AO, Anil C, Gursoy A, Nar A, Inanc M, Bozkurt O, **Tutuncu NB**. Arq Bras Endocrinol Metabol. 2014 Nov;58(8):824-7. Epub 2014 Nov 1.
70. Acromegaly is protective for periodontal tissue - advanced chronic periodontitis is rare in acromegalics. Bascil S, Serinsoz H, **Tutuncu NB**. Bratisl Lek Listy. 2014;115(9):588-92.

71. Is the incidence of temporomandibular disorder increased in polycystic ovary syndrome? Soydan SS, Deniz K, Uckan S, Unal AD, **Tutuncu NB**. Br J Oral Maxillofac Surg. 2014 Nov;52(9):822-6. doi: 10.1016/j.bjoms.2014.07.100. Epub 2014 Aug 12.
72. The relationship between thyroid volume and malignant thyroid disease. Duran AO, Anil C, GURSOY A, Nar A, Altundag O, Inanc M, Bozkurt O, **Tutuncu NB**. Med Oncol. 2014 Jan;31(1):814. doi: 10.1007/s12032-013-0814-2. Epub 2013 Dec 12.
73. The **ORIGIN Trial** Investigators. Predictors of Non severe and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the **ORIGIN Trial**. Diabetes Care. 2014 Oct 28. pii: DC_141329. [Epubahead of print]
74. Cukierman-Yaffe T, Bosch J, Diaz R, Dyal L, Hancu N, Hildebrandt P, Lanas F, Lewis BS, Marre M, Yale JF, Yusuf S, Gerstein HC; **ORIGIN** Investigators. Effects of basal insulin glargine and **omega-3 fatty acid** cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the **ORIGIN trial**. Lancet Diabetes Endocrinol. 2014 Jul;2(7):562-72.
75. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; **ELIXA Investigators**. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.
76. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; **ELIXA Investigators**. Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. Epub 2015 Feb 12.
77. Serum Adiponectin Level as a Predictor of Subclinical Cushing's Syndrome in Patients with Adrenal Incidentaloma. Dogruk Unal A, Ayturk S, Aldemir D, **Bascil Tutuncu N**. Int J Endocrinol. 2016;2016:8519362. doi: 10.1155/2016/8519362. Epub 2016 Aug 30.

78. [Metformin Decreases Thyroid Volume and Nodule Size in Subjects with Insulin Resistance: A Preliminary Study.](#) Anil C, Kut A, Atesagaoglu B, Nar A, **Bacil Tutuncu N**, Gursoy A. Med Princ Pract. 2016;25(3):233-6. doi: 10.1159/000442821. Epub 2015 Nov 30.
79. [Effects of short term mild L-Thyroxine suppression therapy on myocardial functions, and its assessment with tissue Doppler imaging.](#) Bozkus Y, Sunger A, Yildirir A, **Bacil Tutuncu N**. Minerva Endocrinol. 2016 Jun;41(2):147-56. Epub 2014 Nov 12.
80. [An international survey on hypoglycemia among insulin-treated type I and type II diabetes patients: Turkey cohort of the non-interventional IO HAT study.](#)
81. Emral R, Tetiker T, Sahin I, Sari R, Kaya A, Yetkin İ, Cil SU, **Tütüncü NB**; IO HAT investigator group. BMC Endocr Disord. 2018 Feb 13;18(1):9. doi: 10.1186/s12902-018-0238-2. PMID:29433560
82. [Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Mildly to Moderately Iodine-Deficient Region? A Prospective Study.](#) Demir C, Anil C, Bozkus Y, Mousa U, Kut A, Nar A, Tutuncu NB. Med Princ Pract. 2018 Jan 23. doi: 10.1159/000486748. [Epub ahead of print]
83. [An international survey on hypoglycemia among insulin-treated type I and type II diabetes patients: Turkey cohort of the non-interventional IO HAT study.](#) Emral R, Tetiker T, Sahin I, Sari R, Kaya A, Yetkin İ, Cil SU, **Tütüncü NB**; IO HAT investigator group. BMC Endocr Disord. 2018 Feb 13;18(1):9. doi: 10.1186/s12902-018-0238-2. PMID:29433560
84. [Turkish nationwide survey of glycemic and other Metabolic parameters of patients with Diabetes mellitus \(TEMD study\).](#) Sonmez A, Haymana C, Bayram F, Salman S, Dizdar OS, Gurkan E, Kargili Carlıoglu A, Barcin C, Sabuncu T, Satman I; TEMD Study Group. Diabetes Res Clin Pract. 2018 Dec;146:138-147. doi: 10.1016/j.diabres.2018.09.010. Epub 2018 Sep 20.